Ethel D Weld1, Md Sohel Rana2, Ronald H Dallas3, Andres F Camacho-Gonzalez4,5, Patrick Ryscavage6, Aditya H Gaur3, Rana Chakraborty4,5, Susan Swindells7, Charles Flexner1, Allison L Agwu8. 1. Divisions of Clinical Pharmacology and Infectious Diseases, Johns Hopkins University, Baltimore, MD. 2. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN. 4. Division of Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, GA. 5. Ponce Family and Youth Clinic, Grady Infectious Diseases Program, Grady Health Systems, Atlanta, GA. 6. Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD. 7. Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE. 8. Divisions of Adult and Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.
OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.
Authors: Bret J Rudy; Jane C Lindsey; Patricia M Flynn; Ronald J Bosch; Craig M Wilson; Michael E Hughes; Steven D Douglas Journal: AIDS Res Hum Retroviruses Date: 2006-03 Impact factor: 2.205
Authors: David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen Journal: Lancet Date: 2017-07-24 Impact factor: 79.321
Authors: Julie H Levison; Catherine Orrell; Sébastien Gallien; Daniel R Kuritzkes; Naishin Fu; Elena Losina; Kenneth A Freedberg; Robin Wood Journal: PLoS One Date: 2012-03-13 Impact factor: 3.240
Authors: Kathrine Meyers; Kristina Rodriguez; Robert W Moeller; Ilana Gratch; Martin Markowitz; Perry N Halkitis Journal: PLoS One Date: 2014-12-11 Impact factor: 3.240
Authors: Natasha Mack; Emily M Evens; Elizabeth E Tolley; Kate Brelsford; Caroline Mackenzie; Cecilia Milford; Jennifer A Smit; Joshua Kimani Journal: J Int AIDS Soc Date: 2014-09-08 Impact factor: 5.396
Authors: Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner Journal: Lancet HIV Date: 2019-12-20 Impact factor: 12.767
Authors: Karine Dubé; Danielle M Campbell; Kelly E Perry; John T Kanazawa; Parya Saberi; John A Sauceda; Tonia Poteat; David Evans Journal: AIDS Res Hum Retroviruses Date: 2020-09-14 Impact factor: 2.205
Authors: Morgan M Philbin; Sadie Bergen; Carrigan Parish; Deanna Kerrigan; Elizabeth N Kinnard; Sarah Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Michael Vaughn; José I Gutierrez; Margaret A Fischl; Maria Alcaide; Lisa R Metsch Journal: AIDS Behav Date: 2021-10-14